January 26, 2024
1 min watch
Save
VIDEO: Faricimab dosing interval may extend up to 20 weeks in wet AMD, DME
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Michael A. Singer, MD, presents data on dosing intervals for faricimab as a treatment for wet age-related macular degeneration and diabetic macular edema.
“Over 50% of people in both wet AMD and DME who were currently in the 16-week arm didn’t really need a shot based on disease rescue criteria, and they could go to 20 weeks,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Singer M, et al. Faricimab extended dosing in the phase 3 YOSEMITE/RHINE and TENAYA/LUCERNE trials. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Disclosures:
Singer reports speaking and consulting for Genentech and previously consulting for Novartis.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.